Gastrointestinal adverse events of tirzepatide in the treatment of type 2 diabetes mellitus A meta-analysis and trials sequential analysis

首页 > 成果 > 详情

认领

导出

Link by DOI

反馈

作者信息关键词期刊信息基础信息归属信息摘要

成果类型：

期刊论文

作者：

Tong, Keke;Yin, Shuang;Yu, Yunfeng;Yang, Xinyu;Hu, Gang;...

通讯作者：

Liu, ZJ

作者机构：

[Yu, Yunfeng; Hu, Gang; Zhang, Fei; Tong, Keke; Yang, Xinyu; Yin, Shuang] Hunan Univ Chinese Med, Changsha, Peoples R China.

[Tong, Keke] Hosp Hunan Univ Tradit Chinese Med, Changde, Peoples R China.

[Yu, Yunfeng; Hu, Gang; Liu, Zhenjie] Hunan Univ Chinese Med, Hosp 1, Changsha, Peoples R China.

[Liu, Zhenjie] Hunan Univ Chinese Med, Hosp 1, Changsha 410007, Hunan, Peoples R China.

通讯机构：

[Liu, ZJ ] H

Hunan Univ Chinese Med, Hosp 1, Changsha 410007, Hunan, Peoples R China.

语种：

英文

关键词：

gastrointestinal adverse events;meta-analysis;tirzepatide;trial sequential analysis;type 2 diabetes mellitus

期刊：

MEDICINE

ISSN：

0025-7974

年：

2023

卷：

102

期：

页码：

e35488

DOI：

10.1097/MD.0000000000035488

基金类别：

Innovative project for graduate students of Hunan University of Chinese Medicine [2022CX159]

机构署名：

本校为第一机构

院系归属：

第一中医临床学院

摘要：

BACKGROUND: Tirzepatide (TZP) is a novel drug for type 2 diabetes mellitus (T2DM), but the gastrointestinal (GI) adverse events (AEs) is a limiting factor in clinical application. Therefore, this study systematically evaluated the GI AEs of TZP for T2DM. METHODS: Clinical trials of TZP for T2DM were retrieved from eight databases published only from the establishment of the database to February 2023. Revman5.3 and TSA0.9.5.10 Beta were used for meta-analysis and trials sequential analysis (TSA). RESULTS: Meta-analysis showed that compared with ...

反馈

产权有误：本人成果被他人认领

数据有误：数据基本信息有误

归属有误：成果的院系归属、机构署名归属有误

其他原因：

验证码：

看不清楚，换一个

确定

取消

成果认领

标题：

用户	作者	通讯作者	--
	请选择	请选择	--

确定

取消

Gastrointestinal adverse events of tirzepatide in the treatment of type 2 diabetes mellitus A meta-analysis and trials sequential analysis

反馈

成果认领

提示

该栏目需要登录且有访问权限才可以访问